rsv f vaccine
Vaccineexperimental
Clinical trial activity
16 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
0
Phase 4
3
Earliest trial started Oct 1, 2012 (NCT01709019)
Timeline
Indications
Approved for
Studied for
- Healthy Volunteers · Phase 4
- Metapneumovirus · Phase 1/Phase 2
- Paramyxoviridae Infections · Phase 1
- Pregnancy · Phase 4
- Respiratory Syncytial Viruses · Phase 2
- Respiratory Syncytial Virus Infections · Phase 4
- Respiratory Syncytial Virus Vaccines · Phase 1/Phase 2
- Respiratory Tract Diseases · Phase 2
- Respiratory Tract Infections · Phase 2
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rsv f vaccine
- rsv-f vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07295028 | Phase 1 | Nov 17, 2025 | Emeritus Research, Veritas Research., Corp., Vicebio |
| NCT07097012 | Phase 4 | Oct 16, 2025 | Canadian Center for Vaccinology, Canadian Immunization Research Network, Dalhousie University, Government of Canada, University of British Columbia, University of Ottawa |
| NCT07185399 | Phase 4 | Oct 13, 2025 | Emory University, Open Philanthropy Project |
| NCT06686654 | Phase 1/Phase 2 (Phase 2) | Nov 11, 2024 | Sanofi-Aventis |
| NCT06583031 | Phase 1 | Oct 9, 2024 | Sanofi-Aventis |
| NCT06604767 | Phase 1 | Sep 17, 2024 | Sanofi-Aventis |
| NCT06077149 | Phase 4 | Nov 1, 2023 | University of Rochester |
| NCT04453202 | Phase 2 | Jul 16, 2020 | Janssen Pharmaceutica NV |
| NCT04354480 | Phase 1 | Jun 1, 2020 | Janssen Pharmaceutica NV |
| NCT04071158 | Phase 2 | Oct 1, 2019 | Pfizer |
| NCT03982199 | Phase 2 | Aug 12, 2019 | Janssen Pharmaceutica NV |
| NCT04032093 | Phase 2 | Aug 7, 2019 | Pfizer |
| NCT03026348 | Phase 2 | Jan 1, 2017 | Novavax |
| NCT01960686 | Phase 2 | Oct 1, 2013 | Novavax |
| NCT01709019 | Phase 1 | Oct 1, 2012 | Novavax |
| NCT01704365 | Phase 2 | Oct 1, 2012 | Novavax, PATH |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 4 | 4 | 2 | 2012 |
| Janssen Pharmaceutica NV | For profit | 3 | 3 | 2 | 2019 |
| Sanofi-Aventis | For profit | 3 | 3 | 2 | 2024 |
| Pfizer | For profit | 2 | 2 | 1 | 2019 |
| Canadian Center for Vaccinology | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Canadian Immunization Research Network | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Dalhousie University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Emeritus Research | For profit | 1 | 0 | 1 | 2025 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of Canada | Government | 1 | 0 | 1 | 2025 |
| Open Philanthropy Project | Academic/Hospital | 1 | 0 | 1 | 2025 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of British Columbia | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Veritas Research., Corp. | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Vicebio | For profit | 1 | 1 | 1 | 2025 |
17 organizations
Page 1 / 1